Futura Medical Total Assets
Futura Medical total assets. Based on the latest financial reports, Futura Medical (FUM) holds total assets worth GBX5.22 Million GBX (≈ $635.00 USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see FUM market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Futura Medical (2001–2025)
Total assets of Futura Medical from 2001 to 2025. This chart illustrates how Futura Medical's total assets have evolved over time, based on quarterly financial data. See FUM live share price for real-time trading data and today's change.
Futura Medical - Asset Composition Analysis
Futura Medical Total Assets Breakdown (December 2025)
Futura Medical total assets breakdown as of December 2025. Futura Medical's total assets of GBX5.22 Million consist of 85.7% current assets and 14.3% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 65.2% |
| Accounts Receivable | GBX1.07 Million | 20.5% |
| Inventory | GBX260.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Futura Medical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Futura Medical to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Futura Medical's current assets represent 85.7% of total assets in 2025, a decrease from 99.4% in 2001.
- Cash Position: Cash and equivalents constituted 65.2% of total assets in 2025, down from 86.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 20.5% of total assets.
Futura Medical Competitors by Total Assets
Key competitors of Futura Medical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Futura Medical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 2.47 | 2.06 |
| Quick Ratio | 2.06 | 2.35 | 2.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX2.30 Million | GBX5.66 Million | GBX810.67K |
Futura Medical - Advanced Valuation Insights
This section examines the relationship between Futura Medical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.45 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -61.6% |
| Total Assets | GBX5.22 Million |
| Market Capitalization | $14.78K USD |
Valuation Analysis
Below Book Valuation: The market values Futura Medical's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Futura Medical's assets decreased by 61.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Futura Medical (2001–2025)
The table below shows the annual total assets of Futura Medical from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX5.22 Million ≈ $635.00 |
-61.60% |
| 2024-12-31 | GBX13.59 Million ≈ $1.65K |
+15.01% |
| 2023-12-31 | GBX11.82 Million ≈ $1.44K |
+82.56% |
| 2022-12-31 | GBX6.47 Million ≈ $787.54 |
-45.16% |
| 2021-12-31 | GBX11.80 Million ≈ $1.44K |
+628.54% |
| 2020-12-31 | GBX1.62 Million ≈ $197.12 |
-66.95% |
| 2019-12-31 | GBX4.90 Million ≈ $596.33 |
-54.94% |
| 2018-12-31 | GBX10.88 Million ≈ $1.32K |
+13.25% |
| 2017-12-31 | GBX9.60 Million ≈ $1.17K |
-28.53% |
| 2016-12-31 | GBX13.44 Million ≈ $1.64K |
+143.67% |
| 2015-12-31 | GBX5.52 Million ≈ $671.06 |
-46.61% |
| 2014-12-31 | GBX10.33 Million ≈ $1.26K |
+604.73% |
| 2013-12-31 | GBX1.47 Million ≈ $178.34 |
-54.31% |
| 2012-12-31 | GBX3.21 Million ≈ $390.35 |
+8.68% |
| 2011-12-31 | GBX2.95 Million ≈ $359.17 |
+180.34% |
| 2010-12-31 | GBX1.05 Million ≈ $128.12 |
-49.30% |
| 2009-12-31 | GBX2.08 Million ≈ $252.71 |
+100.10% |
| 2008-12-31 | GBX1.04 Million ≈ $126.29 |
-66.39% |
| 2007-12-31 | GBX3.09 Million ≈ $375.72 |
-26.20% |
| 2006-12-31 | GBX4.18 Million ≈ $509.07 |
+88.72% |
| 2005-12-31 | GBX2.22 Million ≈ $269.74 |
-44.20% |
| 2004-12-31 | GBX3.97 Million ≈ $483.40 |
+53.46% |
| 2003-12-31 | GBX2.59 Million ≈ $315.01 |
+46.60% |
| 2003-01-31 | GBX1.77 Million ≈ $214.87 |
-21.89% |
| 2002-01-31 | GBX2.26 Million ≈ $275.10 |
+572.92% |
| 2001-01-31 | GBX336.00K ≈ $40.88 |
-- |
About Futura Medical
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Fut… Read more